Denis Moro-Sibilot

Denis Moro-Sibilot

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Denis Moro-Sibilot

Thoracic Oncology Unit Teaching Hospital A Michallon, INSERM U823, Grenoble, France

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
MSMark A. Socinski
Mark A. Socinski
RJRobert M. Jotte
Robert M. Jotte
FCFederico Cappuzzo
Federico Cappuzzo
FOFrancisco Orlandi
Francisco Orlandi
DSDaniil Stroyakovskiy
Daniil Stroyakovskiy
MRMartin Reck
Martin Reck
The cancer-cell–killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor–mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated atezolizumab plus bevacizumab plus chemotherapy in patients with metastatic nonsquamous non–small-cell lung cancer (NSCLC) who had not previously received chemotherapy.

20 June 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ASAlice T. Shaw
Alice T. Shaw
DKDong-Wan Kim
Dong-Wan Kim
KNKazuhiko Nakagawa
Kazuhiko Nakagawa
TSTakashi Seto
Takashi Seto
LCLucio Crinó
Lucio Crinó
PJPasi A. Jänne
Pasi A. Jänne
In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associated with marked clinical responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK. Whether crizotinib is superior to standard chemotherapy with respect to efficacy is unknown. We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-positive lung cancer who had received one prior platinum-based regimen. Patients were randomly assigned to receive oral treatment with crizotinib (250 mg) twice daily or intravenous chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 weeks. Patients in the chemotherapy group who had disease progression were permitted to cross over to crizotinib as part of a separate study. The primary end point was progression-free survival. The median progression-free survival was 7.7 months in the crizotinib group and 3.0 months in the chemotherapy group (hazard ratio for progression or death with crizotinib, 0.49; 95% confidence interval [CI], 0.37 to 0.64; P<0.001). The response rates were 65% (95% CI, 58 to 72) with crizotinib, as compared with 20% (95% CI, 14 to 26) with chemotherapy (P<0.001). An interim analysis of overall survival showed no significant improvement with crizotinib as compared with chemotherapy (hazard ratio for death in the crizotinib group, 1.02; 95% CI, 0.68 to 1.54; P=0.54). Common adverse events associated with crizotinib were visual disorder, gastrointestinal side effects, and elevated liver aminotransferase levels, whereas common adverse events with chemotherapy were fatigue, alopecia, and dyspnea. Patients reported greater reductions in symptoms of lung cancer and greater improvement in global quality of life with crizotinib than with chemotherapy. Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced non–small-cell lung cancer with ALK rearrangement. (Funded by Pfizer; ClinicalTrials.gov number, NCT00932893.)

1 November 2019 in The Lancet
Verified
Journal Article
Closed access
LPLuis Paz-Ares
Luis Paz-Ares
MDMikhail Dvorkin
Mikhail Dvorkin
YCYuanbin Chen
Yuanbin Chen
NRNiels Reinmuth
Niels Reinmuth
KHKatsuyuki Hotta
Katsuyuki Hotta
MWMichael Williamson
Michael Williamson

1 March 2017 in The Lancet
Verified
Journal Article
Closed access
JSJean-Charles Soria
Jean-Charles Soria
DTDaniel S W Tan
Daniel S W Tan
RCRita Chiari
Rita Chiari
YWYI-LONG WU
YI-LONG WU
LPLuis Paz-Ares
Luis Paz-Ares
GCGilberto de Castro
Gilberto de Castro

1 May 2019 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
MRMartin Reck
Martin Reck
TMTony S K Mok
Tony S K Mok
MNMakoto Nishio
Makoto Nishio
RJRobert M Jotte
Robert M Jotte
FCFederico Cappuzzo
Federico Cappuzzo
TMTony Sk Mok
Tony Sk Mok

1 April 2016 in The Lancet
Verified
Journal Article
Closed access
GZGérard Zalcman
Gérard Zalcman
JMJulien Mazieres
Julien Mazieres
JMJacques Margery
Jacques Margery
LGLaurent Greillier
Laurent Greillier
CAClarisse Audigier-Valette
Clarisse Audigier-Valette
F(French Cooperative Thoracic Intergroup (IFCT)
French Cooperative Thoracic Intergroup (IFCT)